换一批Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
第一作者：
Gui-shuang,Ying
第一单位：
Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, Philadelphia, Pennsylvania 19104, USA. gsying@mail.med.upenn.edu
作者：
医学主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);血管生成抑制剂(Angiogenesis Inhibitors);队列研究(Cohort Studies);女(雌)性(Female);荧光素血管造影术(Fluorescein Angiography);人类(Humans);玻璃体内注射(Intravitreal Injections);男(雄)性(Male);中年人(Middle Aged);时间因素(Time Factors);体层摄影术, 光学相干(Tomography, Optical Coherence);治疗结果(Treatment Outcome);血管内皮生长因子A(Vascular Endothelial Growth Factor A);视敏度(Visual Acuity);湿性黄斑变性(Wet Macular Degeneration)
DOI
10.1016/j.ophtha.2012.07.042
PMID
23047002
发布时间
2022-03-30
- 浏览26
Ophthalmology
122-9页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
